

## PRODUCTS

### Pediatric Vision Test System

The Enfant pediatric vision testing system can be used to test preverbal children for visual deficits. The system can be used for children as young as 6 months of age. For more information, contact Diopsys Inc. by visiting [www.diopsys.com](http://www.diopsys.com) or by calling 973-244-0622.

### Phototherapy for Jaundice

The neoBLUE mini LED phototherapy device emits blue light to help in the breakdown of bilirubin and the treatment of newborn jaundice. For more information, contact Natus Medical Inc. by calling 650-802-0400 or visiting [www.natus.com](http://www.natus.com).

### Moisturizer for Dry Skin

Amlactin XL contains a lactic acid and alpha-hydroxy blend to moisturize dry skin. The lotion is available without a prescription. For more information, contact Upsher-Smith Laboratories Inc. by visiting [www.upsher-smith.com](http://www.upsher-smith.com) or by calling 800-654-2299.

### Rapid Strep A Test

The Directigen EZ Strep A test provides results in 5 minutes. The test has an overall accuracy, sensitivity, and specificity of 97.7%, 95.2%, and 99.0%, respectively. For more information, contact Becton, Dickinson & Co. by visiting [www.bd.com](http://www.bd.com) or by calling 800-638-8663.

### Swabs for Culture Collection

The CultureSwab MaxV comes in a gas-impermeable package that is flushed with nitrogen to protect the media from oxidation and moisture exposure. For more information, contact Becton, Dickinson, and Co., by calling 800-638-8663 or 410-316-4000.

### Valtrex Label Change: Nursing

GlaxoSmithKline is changing the label of Valtrex (valacyclovir) caplets to reflect new data on nursing mothers. After oral administration of 500 mg of the drug, five nursing mothers had peak acyclovir concentrations in breast milk ranging from 0.5 to 2.3 times the corresponding maternal acyclovir serum concentrations. A 500-mg dosage of Valtrex twice daily would provide a nursing infant with an oral acyclovir dosage of approximately 0.6 mg/kg per day—less than 2% of the exposure obtained after administration of a standard neonatal dosage of 30 mg/kg per day of intravenous acyclovir. Valtrex should be administered to a nursing mother with caution and only when indicated. For more information, contact GlaxoSmithKline by calling 888-825-5249.

### Custom Medical Lighting

Custom modular lighting is available in various configurations, including flexible gooseneck arms, spotlights, and different light intensities, for medical exam rooms. For more information, contact Sunnex Inc. by visiting [www.sunnexonline.com](http://www.sunnexonline.com) or by calling 800-445-7869.

### Once-Daily Galantamine Approved

A new, long-acting form of galantamine has been approved for the treatment of mild to moderate Alzheimer's disease. The once-daily option is formulated with

a rate-controlling membrane that gradually releases the medication over 24 hours. For more information, contact Janssen Pharmaceutica Products L.P. by calling 800-526-7736 or by visiting [www.us.reminyl.com](http://www.us.reminyl.com).

### Abraxane Approved

Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension, albumin-bound) has been approved for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or

relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. For more information, contact American Pharmaceutical Partners Inc. by visiting [www.abraxane.com](http://www.abraxane.com) or by calling 800-551-7176.

### New Dosage of femhrt Approved

A new dosage regimen of the medication femhrt 0.5 mg/2.5 mcg (norethindrone acetate/ethinyl estradiol) has been approved. The drug can be used to treat moderate to severe vasomotor symptoms associated with menopause, and also to prevent postmenopausal osteoporosis in

women who have an intact uterus. For more information, contact Warner Chilcott Co. by calling 800-521-8813 or 973-442-3200.

### Lighted Ear Curette Tips

The Lighted FlexLoop and Lighted InfantScoop ear curette tips combine single-use tips with an LED light source to help visualize the procedure. The FlexLoop has a 4-mm oval tip for normal curettage. The InfantScoop has a 2-mm tip for smaller ears. For more information, contact Bionix Medical Technologies by visiting [www.bionix.com](http://www.bionix.com) or by calling 800-551-6810.

# Change is in the Air

## Introducing ATROVENT® HFA:

### The same medication, now in a different formulation

- ATROVENT® (ipratropium bromide) Inhalation Aerosol (CFC) will not be available after December 2005
  - ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol has demonstrated comparable safety and efficacy to the CFC formulation
  - Re-evaluate your patients on ATROVENT® Inhalation Aerosol (CFC) at their next office visit and consider the benefits of switching to SPIRIVA® HandiHaler®
  - For patients switching from ATROVENT® Inhalation Aerosol (CFC) to ATROVENT® HFA, a new prescription specifying "ATROVENT® HFA" will be necessary
- 
- ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema, but is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response
  - ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to ipratropium bromide or other ATROVENT® HFA Inhalation Aerosol components. Immediate hypersensitivity reactions may occur after administration of ipratropium bromide, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis and oropharyngeal edema. ATROVENT® HFA Inhalation Aerosol is also contraindicated in patients who are hypersensitive to atropine or its derivatives
  - Inhaled medicines, including ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol, may cause paradoxical bronchospasm. If this occurs, treatment with ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol should be stopped and other treatments considered
  - ATROVENT® HFA (ipratropium bromide HFA) Inhalation Aerosol should be used with caution in patients with narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction. Patients should avoid spraying the aerosol into their eyes. This may result in precipitation or worsening of narrow-angle glaucoma, mydriasis, eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Should any combination of these symptoms develop, patients should consult their physician immediately
  - The most common drug-related adverse events were dry mouth (1.6% of ATROVENT® HFA Inhalation Aerosol and 0.9% of ATROVENT® Inhalation Aerosol CFC patients), and taste perversion (bitter taste) (0.9% of ATROVENT® HFA Inhalation Aerosol and 0.3% of ATROVENT® Inhalation Aerosol CFC patients)
  - SPIRIVA HandiHaler is intended as a once-daily maintenance treatment for COPD and is not indicated for the initial treatment of acute episodes of bronchospasm, i.e., rescue therapy. SPIRIVA HandiHaler is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, i.e., ipratropium or to any component of this product. The most commonly reported adverse drug reaction was dry mouth, which was usually mild and often resolved during continued treatment. Other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurred vision, glaucoma, urinary difficulty and urinary retention. Inhaled medicines, including SPIRIVA, may cause paradoxical bronchospasm. If this occurs, treatment with SPIRIVA should be stopped and other treatments considered

Please see Brief Summary of Prescribing Information for ATROVENT® HFA Inhalation Aerosol and SPIRIVA® HandiHaler® on pages following this advertisement.

**SPIRIVA® HandiHaler®**  
(tiotropium bromide inhalation powder)

**ATROVENT® HFA**  
(ipratropium bromide HFA)  
INHALATION AEROSOL 17 mcg per puff

